Sana Biotechnology, Inc.

Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA, join Sana Board of Directors SEATTLE — Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today that Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA, have been appointed to the Sana Board of Directors. “Josh, Alise, and […] The post Sana Biotechnology Announces Appointments to its Board of Directors appeared first on Sana Biotechnology.

SEATTLE — Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today that Ke Liu, M.D., Ph.D., has joined the senior leadership team as Sana’s Head of Regulatory Affairs & Strategy. Dr. Liu joins Sana after more than 17 years at the U.S. Food and Drug Administration (FDA). Dr. Liu most […] The post Sana Biotechnology Builds Key Regulatory Capabilities as Ke Liu, M.D., Ph.D., Joins Senior Leadership Team appeared first on Sana Biotechnology.

Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today the acquisition of Oscine Corp. The post Sana Biotechnology Announces Acquisition of Oscine appeared first on Sana Biotechnology.

SEATTLE—September 3, 2020 —Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today two additions to its senior leadership team. Ed Rebar, Ph.D., joins the company as Chief Technology Officer and Terry Fry, M.D. joins as SVP, Head of T Cell Therapeutics. “Ed and Terry are world class scientists who will […] The post Sana Biotechnology Strengthens Senior Research Leadership Team with Ed Rebar, Ph.D. and Terry Fry, M.D. appeared first on Sana Biotechnology.

SEATTLE — Sana Biotechnology, Inc. (Sana), focused on engineering cells as medicines for patients, announced today the funding of all tranches of its initial financing, raising over $700 million.  With this financing, Sana’s shareholders include ARCH Venture Partners, Flagship Pioneering, Canada Pension Plan Investment Board, Baillie Gifford, F-Prime Capital, Alaska Permanent Fund, the Public Sector Pension […] The post Sana Biotechnology Announces Completion of Initial Financing appeared first on Sana Biotechnology.

SEATTLE — Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines for patients, announced today that Stacey Ma, Ph.D. joined the company as Executive Vice President, Technical Operations, where she will oversee process and analytical development, supply chain, quality, and global manufacturing operations. She will be a member of the Sana […] The post Stacey Ma, Ph.D., Joins Sana Biotechnology as Executive Vice President, Technical Operations appeared first on Sana Biotechnology.

SEATTLE — Sana Biotechnology, Inc. (Sana), a new company focused on creating and delivering engineered cells as medicines for patients, announced its launch today. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. […] The post Sana Biotechnology Launches Focusing on Engineering Cells to Create a New Class of Medicines appeared first on Sana Biotechnology.